Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT02299505 · COMPLETED
Trial details
- NCT number
- NCT02299505
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-09
- Primary completion
- 2016-06-16
- Enrollment
- 306
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.